Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2024.11.034 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Zhan-Ming Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Jiangbei Mental Health Center, Chongqing, China. Hauptthemen laut MEDLINE: Ketamine, Electroconvulsive Therapy, Major Depressive Disorder, Bipolar Disorder. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Program key projects.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD. METHODS: Randomized controlled trials (RCTs) comparing IV ketamine and ECT in terms of efficacy, safety, and tolerability for MDD or BD were identified and reviewed. Three independent investigators extracted relevant data, which was synthesized using RevMan 5.3 software under a random effects model. RESULTS: Five RCTs encompassing 664 patients diagnosed with MDD or BD were analyzed. At 24 h post-initial treatment, IV ketamine demonstrated a statistically greater reduction in depressive symptoms compared to ECT (standardized mean difference (SMD) = -0.49, 95 % CI = -0.96 to -0.03, I2 = 77 %; P = 0.04). However, no significant differences were observed between groups in terms of the study-defined response (risk ratio (RR) = 1.49, 95 % CI = 0.08 to 28.42, I2 = 0 %; P = 0.79) at 24 h. Similarly, no notable differences were found for depressive symptom improvement (SMD = -0.48, 95 % CI = -2.41 to 1.45, I2 = 99 %; P = 0.63), the study-defined response (RR = 0.96, 95 % CI: 0.70 to 1.31, I2 = 75 %; P = 0.79) or remission (RR = 0.91, 95 % CI: 0.45 to 1.82, I2 = 90 %; P = 0.78) at the end-of-treatment visit. Among the three RCTs (60 %) comparing the neurocognitive outcomes of IV ketamine and ECT through varying test batteries, results were inconsistent. IV ketamine was associated with marked increases in dissociation, blurred vision, dizziness, and diplopia, while ECT led to a significant rise in muscle pain (all Ps 0.05). CONCLUSION: IV ketamine demonstrates a faster onset of antidepressant effects compared to ECT, despite both treatments yielding comparable outcomes at the end-of-treatment visit for patients with MDD or BD. However, large-scale RCTs are required to thoroughly evaluate the long-term efficacy and safety of IV ketamine relative to ECT in these populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Jiangbei Mental Health Center, Chongqing, China.
- The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
- The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China; Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical Universi…
- Chongqing Eleventh People's Hospital, Chongqing, China.
- The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China. Electronic address: weixin@163.com.
Förderung
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Program key projects
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- National Clinical Key Specialty Project Foundation
- Guangxi Zhuang Autonomous Region Health Department
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Shi, Z. M., Lan, X. J., Chen, Q., Chen, J. J., Su, Z. A., Huang, X. B., Ning, Y. P., Yang, X. H., Wei, X., & Zheng, W. (2025). Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.11.034
Vancouver
Shi ZM, Lan XJ, Chen Q, Chen JJ, Su ZA, Huang XB, et al. Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2024.11.034
BibTeX
@article{Shi2025,
author = {Shi, Zhan-Ming and Lan, Xian-Jun and Chen, Qing and Chen, Jun-Jun and Su, Zhi-Ang and Huang, Xing-Bing and Ning, Yu-Ping and Yang, Xin-Hu and Wei, Xin and Zheng, Wei},
title = {Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2024.11.034}
}
EUVIMED